Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround

Executive Summary

Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company

You may also be interested in...



Lilly Zyprexa Marketing Going “Back to Basics” With Focus On Efficacy

Lilly is taking a "back to basics" approach on marketing for its atypical antipsychotic Zyprexa to grow U.S. market share

Lilly Zyprexa Marketing Going “Back to Basics” With Focus On Efficacy

Lilly is taking a "back to basics" approach on marketing for its atypical antipsychotic Zyprexa to grow U.S. market share

Risperdal Consta Priced Aggressively; J&J Sets High Premium To Zyprexa

Johnson & Johnson's Risperdal Consta (risperidone) is being launched at approximately twice the daily cost of Lilly's market-leading antipsychotic Zyprexa (olanzapine)

Related Content

UsernamePublicRestriction

Register

PS043667

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel